STOCK TITAN

Rhythm Pharmaceuticals (RYTM) Stock News

RYTM NASDAQ

Rhythm Pharmaceuticals, Inc. develops and commercializes therapies for rare neuroendocrine diseases, centered on IMCIVREE (setmelanotide), an MC4R agonist for hyperphagia and severe obesity linked to rare MC4R pathway disorders. Company updates commonly cover U.S. and international commercialization of setmelanotide, regulatory authorizations and label expansions for acquired hypothalamic obesity, Bardet-Biedl syndrome, POMC/PCSK1 deficiency and LEPR deficiency, and safety information tied to approved uses.

Rhythm news also follows clinical data from setmelanotide studies, including acquired hypothalamic obesity and genetically caused MC4R pathway diseases, along with development of investigational MC4R agonists bivamelagon and RM-718 and preclinical small molecules for congenital hyperinsulinism. Recurring corporate items include financial results, specialty-pharmacy access arrangements, healthcare conference presentations and board governance changes.

Rhea-AI Summary

Rhythm Pharmaceuticals (RYTM) presented two-year Phase 3 TRANSCEND results showing sustained BMI reductions with continuous setmelanotide treatment for acquired hypothalamic obesity.

Mean body mass index (BMI) changes at two years were -18.8% with continuous treatment and -16.5% among patients who switched from placebo after one year. Of 125 patients entering the extension, 81 had completed two years at analysis: 54 receiving continuous treatment and 27 switching from placebo. All extension participants received open-label setmelanotide, meaning treatment was known. The safety profile was generally consistent with previous acquired hypothalamic obesity trials. A global expert panel also presented a consensus disease definition and diagnostic criteria at ObesityWeek 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.49%
Tags
none
-
Rhea-AI Summary

Rhythm Pharmaceuticals (Nasdaq: RYTM) announced expanded NICE guidance allowing adults with genetically confirmed Bardet-Biedl syndrome to access funded IMCIVREE treatment. The National Institute for Health and Care Excellence recommendation expands reimbursement eligibility through the National Health Service. The updated recommendation covers adults in England, Wales and Northern Ireland.

The guidance broadens NICE's May 2024 recommendation, which had limited treatment initiation to patients ages 6 to 17 years. NICE considered additional clinical, real-world and disease-burden evidence, including longer-term treatment data. Its assessment recognized the burden of excessive hunger and obesity associated with Bardet-Biedl syndrome, including effects on quality of life, mental health, mobility, education and independence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.04%
Tags
none
-
Rhea-AI Summary

Rhythm Pharmaceuticals (Nasdaq: RYTM) reported third-quarter 2026 IMCIVREE revenue of $92.1 million, reflecting growth in its acquired hypothalamic obesity business. Revenue rose 29% sequentially, versus $51.3 million a year earlier. Net loss attributable to common stockholders narrowed to $42.4 million, or $0.61 per share, from $54.3 million, or $0.82 per share.

More than 700 U.S. patient start forms had been received by September 30. Japan's commercial launch is underway. Rhythm secured a five-year loan facility providing access to up to $750 million and agreed to $350 million in fixed payments over four years to reduce LG Chem royalties to 1%. Rhythm expects to initiate pivotal bivamelagon trials in acquired hypothalamic obesity by year-end 2026 and a Prader-Willi syndrome study in 2027, pending FDA alignment. September 30 cash and short-term investments totaled approximately $320.9 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.49%
Tags
Rhea-AI Summary

Rhythm Pharmaceuticals (Nasdaq: RYTM) amended its bivamelagon license with LG Chem, replacing portfolio royalties with a 1% rate and adding fixed payments. The rate replaces low-to-mid-single-digit royalties on global net sales of its MC4R portfolio, including setmelanotide, bivamelagon and RM-718, starting January 1, 2029, or first commercial bivamelagon sales, if earlier.

Rhythm owes $350 million in additional installments through September 2029. An additional milestone of up to $200 million is tied to $3 billion in annual portfolio net sales; existing milestones of up to $205 million remain. A five-year loan facility led by KKR’s HealthCare Royalty with Blackstone provides up to $750 million, including $500 million committed. An initial $250 million draw is expected at closing on November 6, 2026. Borrowings carry SOFR, a benchmark interest rate, plus 4.60%, with no equity component or scheduled principal repayments before maturity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.49%
Tags
none
-
Rhea-AI Summary

Rhythm Pharmaceuticals (RYTM) will report third-quarter 2026 financial results and provide a corporate update on November 3, 2026. The live call and webcast begin at 8:00 a.m. ET.

CEO David Meeker will join a fireside chat at the Guggenheim Healthcare Innovation Conference on November 9 at 9:00 a.m. ET. CFO Hunter Smith will join a Stifel Healthcare Conference fireside chat on November 11 at 11:20 a.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
earnings date
-
Rhea-AI Summary

Rhythm Pharmaceuticals (RYTM) has commercially launched IMCIVREE (setmelanotide) in Japan for patients with acquired hypothalamic obesity following national insurance price-list inclusion.

The launch follows approval by Japan's Ministry of Health, Labour and Welfare in August 2026. IMCIVREE also received orphan drug designation from the ministry for this condition. Approval was supported by the pivotal Phase 3 TRANSCEND trial, which enrolled 142 patients, including 12 from a Japanese cohort and 10 supplemental patients enrolled in addition to the primary 120-patient cohort. The global study met its primary endpoint, showing a statistically significant 18.8% placebo-adjusted reduction in body mass index, a measure of weight relative to height. Rhythm estimates approximately 5,000 to 8,000 people live with acquired hypothalamic obesity in Japan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
Rhea-AI Summary

Rhythm Pharmaceuticals (RYTM) received Health Canada approval for IMCIVREE (setmelanotide) for weight management in adults and children 4 years and older with acquired hypothalamic obesity (HO).

IMCIVREE, a melanocortin‑4 receptor (MC4R) agonist, is the first targeted therapy approved in Canada to treat acquired HO, a rare condition characterized by accelerated and sustained weight gain following hypothalamic injury. This approval adds to IMCIVREE’s existing Canadian indication, granted in 2023, for patients 6 years and older with obesity due to Bardet‑Biedl syndrome or certain genetically confirmed POMC, PCSK1 or LEPR deficiencies. Health Canada’s decision is based on the pivotal global Phase 3 TRANSCEND trial in 142 patients with acquired HO, which met its primary endpoint with an 18.8% placebo‑adjusted reduction in body mass index. Rhythm plans to support access to IMCIVREE for eligible patients across Canada.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
none
-
Rhea-AI Summary

Rhythm Pharmaceuticals (RYTM) will present new real-world and Phase 3 setmelanotide data in paediatric hypothalamic obesity at ESPE 2026 in Marseille, France.

In a French early-access real-world cohort of 30 patients aged 6 to <18 years with acquired hypothalamic obesity (HO), setmelanotide was associated with mean BMI reductions of 11.5% at 6 months (n=17), 13.4% at 9 months (n=14), 10.5% at 12 months (n=13) and 9.0% at 18 months (n=5). More than 88% of patients achieved ≥0.2-point BMI z-score reductions at all assessed timepoints, with 100% at 12 and 18 months, and patient-reported hunger fell in adolescents.

Post-hoc Phase 3 analyses showed greater improvements versus placebo in multiple cardiometabolic indices, including metabolic syndrome z-BMI (mean change -0.8 vs -0.2; p=0.006) and Fatty Liver Index (-20.6 vs +6.1; p<0.0001). No new safety concerns were observed, and adverse events aligned with prior Phase 3 data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
Rhea-AI Summary

Rhythm Pharmaceuticals (Nasdaq: RYTM) announced that Japan’s Ministry of Health, Labour and Welfare has granted marketing authorization for IMCIVREE (setmelanotide) to treat patients with acquired hypothalamic obesity (HO), the first approved therapy for this condition in Japan.

According to Rhythm, IMCIVREE, a melanocortin‑4 receptor agonist with MHLW orphan drug designation since March 2025, is expected to launch in Japan by the end of 2026, pending final pricing. Approval was supported by the global Phase 3 TRANSCEND trial in 142 acquired HO patients, which achieved a placebo‑adjusted −18.8% reduction in BMI. The study included a Japanese cohort of 12 patients. Rhythm estimates 5,000–8,000 people are living with acquired HO in Japan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
none
Rhea-AI Summary

Rhythm Pharmaceuticals (Nasdaq: RYTM) appointed Manher “AJ” Joshi, M.D., as Chief Medical Officer, effective August 17. Dr. Joshi brings more than 20 years of experience spanning discovery, pivotal trials, global regulatory processes and lifecycle management in rare diseases and other therapeutic areas.

He previously served as Chief Development Officer at Soleno Therapeutics, Chief Medical Officer at Neurona Therapeutics, and held senior clinical leadership roles at Atara Biotherapeutics, Allergan Medical, Synageva BioPharma, Genzyme and other organizations. Rhythm develops treatments for rare neuroendocrine diseases, led by IMCIVREE (setmelanotide), an MC4R agonist approved in the U.S., EU and UK for specific forms of acquired hypothalamic obesity and genetically defined obesity syndromes, and is advancing additional MC4R agonists and preclinical programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
management

FAQ

What is the current stock price of Rhythm Pharmaceuticals (RYTM)?

Rhythm Pharmaceuticals (RYTM) last closed at $112.36.

What is the market cap of Rhythm Pharmaceuticals (RYTM)?

The market cap of Rhythm Pharmaceuticals (RYTM) is approximately $7.8B.